Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
Authors
Keywords
Hepatitis C virus, Cost-effectiveness, Pharmaceutical pricing, Direct-acting antivirals
Journal
Infectious Agents and Cancer
Volume 11, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-04-26
DOI
10.1186/s13027-016-0071-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals
- (2016) Jagpreet Chhatwal et al. PHARMACOECONOMICS
- Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection
- (2015) Gregory T. Everson et al. ANNALS OF INTERNAL MEDICINE
- The Cost-Effectiveness of Sofosbuvir-Based Regimens for Treatment of Hepatitis C Virus Genotype 2 or 3 Infection
- (2015) Benjamin P. Linas et al. ANNALS OF INTERNAL MEDICINE
- Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus
- (2015) Mehdi Najafzadeh et al. ANNALS OF INTERNAL MEDICINE
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States
- (2015) Soumitri Barua et al. ANNALS OF INTERNAL MEDICINE
- A path to eradication of hepatitis C in low- and middle-income countries
- (2015) Camilla S. Graham et al. ANTIVIRAL RESEARCH
- Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
- (2015) Bryony Simmons et al. CLINICAL INFECTIOUS DISEASES
- Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy
- (2015) Stacey B. Trooskin et al. CLINICAL INFECTIOUS DISEASES
- Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern
- (2015) Karen Van Nuys et al. HEALTH AFFAIRS
- Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
- (2015) Andrew J. Leidner et al. HEPATOLOGY
- Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs
- (2015) Anthony Cousien et al. HEPATOLOGY
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C drug affordability
- (2015) Mohga Kamal-Yanni Lancet Global Health
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More